You are here: Industry Insights > Market News > Divi’s Laboratories commence construction of facility near Kakinada

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Divi’s Laboratories commence construction of facility near Kakinada

expresspharmaDecember 03, 2020

Tag: Divi’s Laboratories , facility , Kakinada

Favorites

Divi’s Laboratories announced the commencement of construction of its Unit-III Facility (the Project) at Kona Forest, Ontimamidi Village, Thondangi Mandal, Near Kakinada, East Godavari District, Andhra Pradesh from December 7, 2020.

The company will be investing about Rs 1500 crores out of its internal accruals in a phased manner for the implementation of its Unit III facility.

The operations are likely to commence within 12 to 18 months for the first phase of the project.

All the requisite licenses have been granted by the Government of India and Government of Andhra Pradesh for implementation of the project.

Previous:Pfizer-BioNTech COVID-19 vaccine gets EUA approval from the UK

Next:Genentech gets US FDA nod for Gavreto to treat RET-mutant, RET fusion-positive thyroid cancers

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Divi’s Laboratories commence construction of facility near Kakinada | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

Divi’s Laboratories commence construction of facility near Kakinada

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

Divi’s Laboratories commence construction of facility near Kakinada

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>